GILD
Gilead SciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Bull case: Durable HIV revenue growth, stronger-than-expected adoption of long‑acting therapies (e.g., Cabenuva), and positive late‑stage readouts drive margin expansion and multiple re-rating toward the top analyst target.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.4.
What can break
HIV pricing pressure and competitive share loss
Momentum
25
Value
65
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $146.84 · Bull $170.00 · Bear $103.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-11 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $160.57
Why
Momentum25 · Δ7d -0.4
Value65 · Δ7d -0.4
Sentiment52 · Δ7d -7.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
25
26% active weight
Current posture
7d trendImproving
Δ7d
-0.4
Δ21d
-4.6
Value
65
39% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-0.3
Sentiment
52
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.3
Δ21d
-7.0
Why this grade
Composite grade C. Momentum 25.1 / Value 65.2 / Sentiment 52.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$166.72B
Beta
0.37
Shares Out
1.24B
P/E (TTM)
18.4
P/S (TTM)
5.05
P/FCF (TTM)
28.33
Rev YoY
+5.1%
EPS YoY
+54.3%
Gross Margin
+79.4%
Op Margin
+36.1%
Net Debt
$15.93B
Current Ratio
1.97
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology